DOP2015000005A - Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos - Google Patents

Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos

Info

Publication number
DOP2015000005A
DOP2015000005A DO2015000005A DO2015000005A DOP2015000005A DO P2015000005 A DOP2015000005 A DO P2015000005A DO 2015000005 A DO2015000005 A DO 2015000005A DO 2015000005 A DO2015000005 A DO 2015000005A DO P2015000005 A DOP2015000005 A DO P2015000005A
Authority
DO
Dominican Republic
Prior art keywords
preparation
methods
well
estra
tetraene
Prior art date
Application number
DO2015000005A
Other languages
English (en)
Inventor
Ulrich Bothe
Andrea Rotgeri
Tobias Marquardt
Naomi Barak
Matthias Busemann
Oliver Martin Fischer
Christian Stegmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748225&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2015000005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of DOP2015000005A publication Critical patent/DOP2015000005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

La invención se refiere a inhibidores de AKR1C3 y a métodos para su preparación, su uso para el tratamiento y/o la prevención de enfermedades, así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, en especial de 10 trastornos hemorrágicos y endometriosis.
DO2015000005A 2012-07-10 2015-01-09 Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos DOP2015000005A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012211970 2012-07-10

Publications (1)

Publication Number Publication Date
DOP2015000005A true DOP2015000005A (es) 2015-02-15

Family

ID=48748225

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000005A DOP2015000005A (es) 2012-07-10 2015-01-09 Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos

Country Status (28)

Country Link
US (1) US9512169B2 (es)
EP (1) EP2872524B1 (es)
JP (1) JP6196302B2 (es)
KR (1) KR20150036319A (es)
CN (1) CN104428309B (es)
AP (1) AP2014008179A0 (es)
AR (1) AR092025A1 (es)
AU (1) AU2013289344A1 (es)
BR (1) BR112015000443A2 (es)
CA (1) CA2878485A1 (es)
CL (1) CL2015000039A1 (es)
CO (1) CO7160008A2 (es)
CR (1) CR20150007A (es)
DO (1) DOP2015000005A (es)
EA (1) EA201500112A1 (es)
EC (1) ECSP15000868A (es)
ES (1) ES2603258T3 (es)
HK (1) HK1205743A1 (es)
IL (1) IL236581A0 (es)
MA (1) MA37742B1 (es)
MX (1) MX2015000347A (es)
PE (1) PE20150353A1 (es)
PH (1) PH12015500062A1 (es)
TN (1) TN2015000007A1 (es)
TW (1) TW201402596A (es)
UY (1) UY34899A (es)
WO (1) WO2014009274A1 (es)
ZA (1) ZA201500920B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150118153A (ko) * 2013-02-21 2015-10-21 바이엘 파마 악티엔게젤샤프트 17.베타.-히드록시스테로이드 데히드로게나제 (akr1 c3)의 억제를 위한 에스트라-1,3,5(10),16-테트라엔-3-카르복스아미드
US20170260226A1 (en) * 2014-09-11 2017-09-14 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
CA3047191A1 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－***－４-基）甲酮
WO2018114677A2 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
CN110272465A (zh) * 2019-07-15 2019-09-24 成都贝诺科成生物科技有限公司 阿比特龙衍生物、其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2742331B2 (ja) * 1992-03-31 1998-04-22 ブリテイツシユ・テクノロジー・グループ・リミテツド 癌治療に有用な１７位置換ステロイド
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
ES2200334T3 (es) 1997-04-07 2004-03-01 Wyeth Estra-5(10),7-dieno con actividad estrogenica.
AU2707999A (en) 1998-03-11 1999-09-27 Endorecherche Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
WO2000007576A2 (en) 1998-08-07 2000-02-17 Endorecherche, Inc. INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
EP1284272A4 (en) * 2000-04-24 2003-09-10 Kyowa Hakko Kogyo Kk Estra-1,3,5 (10) -triene
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
MX2008011127A (es) 2006-03-02 2008-10-31 Astellas Pharma Inc INHIBIDOR DE 17ß HSD TIPO 5.
EP2099814A1 (en) 2006-11-30 2009-09-16 Solvay Pharmaceuticals GmbH Substituted estratrien derivatives as 17beta hsd inhibitors
MX2009006454A (es) 2006-12-22 2009-06-26 Hoffmann La Roche Derivados de espiro-piperidina.
EP2172454A4 (en) 2007-07-24 2010-12-08 Astellas Pharma Inc benzimidazole derivative
DE102011083725A1 (de) * 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
UY34899A (es) 2014-02-28
IL236581A0 (en) 2015-02-26
JP6196302B2 (ja) 2017-09-13
CN104428309A (zh) 2015-03-18
US20150210734A1 (en) 2015-07-30
KR20150036319A (ko) 2015-04-07
CA2878485A1 (en) 2014-01-16
US9512169B2 (en) 2016-12-06
AP2014008179A0 (en) 2014-12-31
PH12015500062A1 (en) 2015-03-02
MA37742A1 (fr) 2016-05-31
AR092025A1 (es) 2015-03-18
BR112015000443A2 (pt) 2017-06-27
CL2015000039A1 (es) 2015-03-27
MA37742B1 (fr) 2016-12-30
TN2015000007A1 (en) 2016-06-29
ZA201500920B (en) 2017-01-25
CO7160008A2 (es) 2015-01-15
EP2872524A1 (de) 2015-05-20
MX2015000347A (es) 2015-04-14
ES2603258T3 (es) 2017-02-24
CN104428309B (zh) 2016-09-14
TW201402596A (zh) 2014-01-16
EP2872524B1 (de) 2016-08-24
CR20150007A (es) 2015-03-13
WO2014009274A1 (de) 2014-01-16
AU2013289344A1 (en) 2015-02-05
ECSP15000868A (es) 2016-01-29
PE20150353A1 (es) 2015-03-28
EA201500112A1 (ru) 2015-07-30
JP2015522050A (ja) 2015-08-03
HK1205743A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CO2017011851A2 (es) Compuestos novedosos
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
CR20150326A (es) Inhibidores de autotaxina
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CR20160033A (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromático-bencil-amida
IN2014DN06501A (es)
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.